After a busy year, at-home testing company Everlywell is growing through two acquisitions. It bought telehealth practice PWNHealth and another at-home lab testing company.
As Covid-19 joins the ranks of cancer and chronic diseases to be tracked and prevented through testing, health plans will need testing solutions that can be distributed quickly and at scale.
After Everlywell received an emergency use authorization last year from the FDA for its at-home collection kit, the agency gave Everlywell the green light to sell its test kits without requiring a prescription.
Ellume, whose at-home Covid-19 test was cleared by the FDA in December, got a $232 million contract from the Department of Health and Human Services to deliver 8.5 million tests.
Few people question whether care delivery will continue to migrate out of the hospital into new settings such as the home. The better question is, what services – specifically – will migrate to the home, and what innovations are necessary to support these migrations?
During a panel discussion at the J.P. Morgan Healthcare Conference, three physicians from Stanford Medicine discussed the investment opportunities that can help accelerate innovation in healthcare in the coming year.
The Austin-based startup has distributed more than 500,000 Covid-19 test kits to date, and expects total sales to quadruple by the end of the year.
The retailer is offering at-home Covid-19 testing kits, including nasal swabs and saliva test kits, from Los Angeles-based startup myLab Box.
Humana will send 1 million screening kits to its members for managing diabetes and screening for colorectal cancer. The at-home tests are intended to offset screenings and other preventive care being pushed back due to Covid-19.